Zhuzhou Qianjin Pharmaceutical Adjusts Valuation Amidst Growth Challenges and Market Underperformance

Zhuzhou Qianjin Pharmaceutical Co., Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a shift in the stock's valuation metrics, indicating a transition from a previously higher valuation perspective to a more balanced assessment. Key financial metrics reveal a P/E ratio of 19, alongside a price-to-book value of 1.78. The company's enterprise value to EBIT stands at 14.47, while the EV to EBITDA ratio is recorded at 12.56. Additionally, the EV to sales ratio is noted at 1.48, and the dividend yield is positioned at 2.87%. The latest return on capital employed (ROCE) is 12.30%, with a return on equity (ROE) of 9.45%. Despite these metrics, the company has faced challenges in long-term growth, with net sales increasing at an annual rate of 0.04% and operating profit at 1.79% over the past five years. The most recent quarter ending December 2025 showed a decline in operating cash flow and a notable increase in the debt-equity ratio. Furthermore, Zhuzhou Qianjin Pharmaceutical has underperformed the market, generating a return of 8.60% over the last year compared to the China Shanghai Composite's 22.49%. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.